Client News

Roquefort Therapeutics plc: Pre-clinical Update
Home / Client News / Roquefort Therapeutics plc: Pre-clinical Update

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to provide an update on progress with its wholly-owned subsidiary, LYRAMID, a pre-clinical biotech company focused on developing first-in-class Midkine inhibiting RNA therapeutic drugs for the treatment of cancer, chronic inflammatory and autoimmune disorders, as well as lung diseases such as COVID-19.

https://www.londonstockexchange.com/news-article/ROQ/pre-clinical-update/15289214

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

APPLY NOW

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

LOGIN

Submit a Comment

Your email address will not be published. Required fields are marked *

Optiva Securities Ltd
118 Piccadilly
London W1J 7NW

Tel +44 (0)20 3137 1902
info@optivasecurities.com
 optivasecurities
@optivalondon
Optiva Securities

KEEP UPDATED

Register to stay updated with the latest news.

    We would like to send you occasional emails about our services and keep you up to date with the latest announcements and news. To join our mailing list, simply click below. You can unsubscribe at any time.

    Optiva Securities Limited is authorised and regulated by the United Kingdom Financial Conduct Authority and are Members of the London Stock Exchange.

    © Copyright Optiva Securities Limited. Registered in England number 3068464
    Share This